PerkinElmer, Inc. has submitted an offer to take over all EUROIMMUN shares. Majority shareholder, company founder and chief executive officer Prof. Dr. med. Winfried Stöcker has already signed the contract to sale his shares. The remaining members of the Management Board will transfer their shares as well. The Management Board and the Supervisory Board of EUROIMMUN AG support the project.
“I am delighted to entrust my company to this proven experts, who, I believe, are able to secure the continuity of what we have successfully built up during the past thirty years,” says Stöcker, who founded the company in Lübeck in 1987.
The economic development of the company remains very positive for many years: Over the last five years, the company has average revenue growth of 19 percent. “Just for this reason it is essential to maintain this status. From today’s point of view, we can still choose our partner, but otherwise I would assume that in the event of my death and the subsequent settlement of an estate, we would get other partners, and then a breakdown of the company could not be ruled out”, says Stöcker, who celebrated his 70th birthday this year.
Research and development will continue to be operated at EUROIMMUN. Stöcker: “We also expect additional impulses by PerkinElmer’s worldwide distribution system.”
In the future, both companies want to cooperate in many areas. The business areas of EUROIMMUN will be maintained in the future. “Only the ownership conditions of the shares change,” says Stöcker. There is no competitive situation between both companies, in fact the business areas will complement each other and will allow very promising synergies.
“I am also extremely excited about bringing together two innovative, results driven cultures with a shared mission of improving global health,” said Robert Friel, chairman and chief executive officer of PerkinElmer. “Having had the opportunity to get to know Professor Stöcker and his leadership team over the last several months has cemented my conviction in this combination and validated our work over the past several years to seek the perfect companion to join PerkinElmer for its next phase of success.”
Chairman of the Board of EUROIMMUN AG will continue to be Prof. Dr. Winfried Stöcker.
